Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB after the cryptocurrency achieved a new all-time high. The company aims to bolster its balance sheet by acquiring BNB, raising up to $520 million through a combination of an equity line of credit and a stock-purchase agreement. Windtree previously announced intentions to buy $200 million in BNB. The company's CEO emphasized that securing additional funds for BNB is crucial to their strategy. BNB, the fifth-largest cryptocurrency, recently saw its price peak at $808 before declining. Windtree's stock has experienced significant growth lately, mirroring a trend among publicly traded companies diversifying their holdings with digital assets beyond Bitcoin. Other companies, including Chinese firm Nano Labs, are also investing heavily in BNB, showcasing a broader acceptance of cryptocurrencies as treasury assets. The growing interest in crypto among traditional businesses is reshaping the financial landscape.

Source 🔗